Navigation Links
'Cancer Research' Has Published a Paper on the Activity of MM-121, an ErbB3 Inhibitor, in Ligand-dependent Tumors
Date:3/16/2010

Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, Dana-Farber/Harvard Cancer Center, Cell Signaling Technology, Harvard Medical School and Merrimack Pharmaceuticals collaborated on the MM-121 research. Researchers looked at MM-121 in combination with Erbitux to study efficacy in preclinical cancer models resistant to other targeted therapies.

Cambridge, Mass. (PRWEB) March 16, 2010 -- "Cancer Research" has published the paper “MM-121 Demonstrates in vivo Efficacy in Ligand-Dependent Tumors.” The paper describes how MM-121, an ErbB3 inhibitor, is effective as a single agent in preclinical models of cancer that are driven by known cancer-associated ligands within the cell. The researchers also found that combining MM-121 with an EGFR inhibitor showed efficacy in preclinical cancer models that are resistant to other targeted therapies. The work was completed through a collaboration between Merrimack Pharmaceuticals, Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, the Dana-Farber/Harvard Cancer Center, Cell Signaling Technology and Harvard Medical School. MM-121’s novel mechanism, designed using a systems biology approach, promises to benefit patients not effectively treated by current therapies targeting overexpressed or mutated oncogenes. Merrimack and sanofi-aventis are currently enrolling patients in a Phase 1/2 study of MM-121 combined with the EGFR inhibitor Tarceva® in patients with non small cell lung cancer.

About Merrimack
Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Copies of the article can be found at http://cancerres.aacrjournals.org/.

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3733734.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Expects to Benefit from the Recently Published Guide to Pricing Reform for Medicine and Medical Services
2. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
3. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
4. Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today
5. Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
6. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
7. Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
8. Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax
9. New Report Just Published: World Prostate Cancer Therapeutics Market Report
10. New Report Just Published: World Endoscopy Systems Market Report
11. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Cancer Research' Has Published a Paper on the Activity of MM-121, an ErbB3 Inhibitor, in Ligand-dependent Tumors
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, ... data on its oral peptide drug candidates, PTG-100 ... of the European Crohn,s and Colitis Organization (ECCO).  ... Barcelona, Spain from February 15 ... detail preclinical data on Protagonist drug candidates PTG-100 ...
(Date:2/16/2017)... Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 Venture ... by a MichBio member organization. They provide an opportunity to interact with peers, make ...
(Date:2/16/2017)... and GREENWICH, Conn. , ... investment firm focused on venture growth investments in ... of Josh Richardson , M.D. to Managing ... in biotechnology companies.  He is a board observer ... roles in Longitude,s investments in Aimmune Therapeutics, Akebia ...
(Date:2/16/2017)... 2017  ArmaGen, Inc., a privately held biotechnology ... severe neurological disorders, today reported preliminary evidence of ... company,s investigational therapy for the treatment of Hurler ... I, or MPS I). The initial results from ... today at the 13 th annual WORLD ...
Breaking Biology Technology:
(Date:2/2/2017)...  Central to its deep commitment to honor ... Japan Prize Foundation today announced the laureates of ... envelope in their respective fields of Life Sciences ... being recognized with the 2017 Japan Prize for ... to the advancement of science and technology, but ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, ... therapies for the treatment of bacterial infections, today ... of antibacterial candidates from Pro Bono Bio Ltd ... prevalence of multi-drug resistant forms of Gram-negative bacteria.  ... Anti Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)... CITY , Jan. 26, 2017  Crossmatch, a ... unveiled a new solution aimed at combatting fraud, waste ... solution was introduced at the Action on Disaster Relief ... key meeting point for UN agencies and foreign assistance ... Fraud, waste and abuse are a largely unacknowledged ...
Breaking Biology News(10 mins):